RecruitingNCT06327516

Lysophosphatidylglycerol in Asthma Pathogenesis


Sponsor

Peking University Third Hospital

Enrollment

250 participants

Start Date

Jan 1, 2015

Study Type

OBSERVATIONAL

Conditions

Summary

The study aims to investigate the relationship between the small molecule metabolite lysophosphatidylglycerol and asthma clinical features and explore its involvement in asthma pathogenesis.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study investigates the role of a molecule called lysophosphatidylglycerol (LPG) in asthma — a chronic lung condition causing wheezing, shortness of breath, and coughing. Researchers believe this naturally occurring lipid (fat molecule) may play a role in the inflammation underlying asthma and hope to better understand how it contributes to the disease. **You may be eligible if...** - You have been clinically diagnosed with asthma **You may NOT be eligible if...** - You also have COPD, bronchiectasis, pneumonia, obstructive sleep apnea, or a malignant tumor - You have acute or chronic respiratory failure - You have severe heart disease - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Peking university third hospital

Beijing, None Selected, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06327516


Related Trials